BTAIBioXcel Therapeutics Inc
BTAI
BioXcel Therapeutics Inc9,842
Mkt Cap
$29.24MVolume
779,730.0052W High
$8.0852W Low
$1.05PE Ratio
-0.15BTAI Fundamentals
Price
$1.06Prev Close
$1.08Open
$1.0850D MA
$1.49Beta
1.48Avg. Volume
2.99MEPS (Annual)
-$5.73P/B
-0.25Rev/Employee
$22,137.93$110.18
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, April 9, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no...
PR Newswire·1d ago
Why Are BioXcel Therapeutics Shares Down Friday?
BioXcel Therapeutics shares fall after a rally as BXCL501 Phase 2 data show promise for treating opioid withdrawal symptoms.read more...
Benzinga·1mo ago
Defense, Biotech, and Aerospace Stories Dominate
Markets are opening Thursday with a mix of defense innovation, biotech progress, aerospace supply chain momentum, and turnaround earnings, highlighting how technology and strategic manufacturing continue to drive investor attention across several sectors. From next-generation biomaterials to counter-drone systems and aerospace electronics, the latest corporate developments suggest continued capital flow toward industries tied to national security, healthcare innovation, and advanced manufacturing. $KBLB, $IBO, $GXAI, $MOBX, $BTAI, $ALTO
24-7 Market News·1mo ago
BioXcel Files SNDA To Expand IGALMI Label For At-Home Setting
(RTTNews) - BioXcel Therapeutics, Inc. (BTAI) said on Tuesday that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for IGALMI, seeking approval...
Nasdaq News: Markets·3mo ago
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders. If...
Business Wire·3mo ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -41.56% and -34.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders. If...
Business Wire·6mo ago
BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study
The company stated that the continued effects and consistent benefits observed with repeat dosing in the trial support the potential of BXCL501 for use in the outpatient setting.
<
1
2
...
>